Acrivon Therapeutics, Inc. Common Stock
ACRVNASDAQHealthcare● Active
$1.41
$-0.02(-1.40%)
Market Cap$44494174
P/E Ratio—
52W High$3.56
52W Low$1.15
Acrivon Therapeutics, Inc. Common Stock (ACRV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACRV · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.49
Est. -$0.49 · +0.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
🔥 6-Quarter EPS Beat Streak
ACRV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.48 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 13, 2026 | -$0.49 | -$0.49 | +0.0% | — | $0.00B | — |
| — Q1 FY2026 | Mar 19, 2026 | -$0.49 | -$0.49 | +0.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.57 | -$0.47 | +17.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.57 | -$0.55 | +3.5% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.57 | -$0.51 | +10.5% | — | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.69 | -$0.60 | +13.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.56 | -$0.59 | -5.4% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.48
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026
EPS Actual
-$0.49
EPS Est.
-$0.49
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 19, 2026
EPS Actual
-$0.49
EPS Est.
-$0.49
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.47
EPS Est.
-$0.57
EPS Surpr.
+17.5%
Revenue
—
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.55
EPS Est.
-$0.57
EPS Surpr.
+3.5%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.51
EPS Est.
-$0.57
EPS Surpr.
+10.5%
Revenue
—
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.60
EPS Est.
-$0.69
EPS Surpr.
+13.0%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.59
EPS Est.
-$0.56
EPS Surpr.
-5.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q3 FY2027 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q2 FY2027 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q1 FY2027 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q4 FY2026 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2026 | $-0.55 | $-0.53 | $-0.50 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +0.0% | $1.89 | $1.92 | +1.59% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +0.0% | $1.64 | $1.70 | +3.66% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +17.5% | $2.28 | $2.07 | -9.21% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +3.5% | $1.25 | $1.31 | +4.80% |
| ▲ Q2 FY2025 | May 14, 2025 | +10.5% | $1.13 | $1.14 | +0.88% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +13.0% | $2.61 | $2.52 | -3.45% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -5.4% | $8.39 | $7.93 | -5.48% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +11.9% | $7.59 | $7.25 | -4.48% |
Q2 FY2026+1.59%
Report Date
May 13, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.89
Price After
$1.92
Q1 FY2026+3.66%
Report Date
Mar 19, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.64
Price After
$1.70
Q4 FY2025-9.21%
Report Date
Nov 13, 2025
EPS Beat/Miss
+17.5%
Price Before
$2.28
Price After
$2.07
Q3 FY2025+4.80%
Report Date
Aug 13, 2025
EPS Beat/Miss
+3.5%
Price Before
$1.25
Price After
$1.31
Q2 FY2025+0.88%
Report Date
May 14, 2025
EPS Beat/Miss
+10.5%
Price Before
$1.13
Price After
$1.14
Q1 FY2025-3.45%
Report Date
Mar 27, 2025
EPS Beat/Miss
+13.0%
Price Before
$2.61
Price After
$2.52
Q4 FY2024-5.48%
Report Date
Nov 13, 2024
EPS Beat/Miss
-5.4%
Price Before
$8.39
Price After
$7.93
Q3 FY2024-4.48%
Report Date
Aug 13, 2024
EPS Beat/Miss
+11.9%
Price Before
$7.59
Price After
$7.25
Avg Beat Reaction-0.89%
Avg Miss Reaction-5.48%
Beat Rate7 / 8 quarters
Largest Move-9.21% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACRV ends December
Acrivon Therapeutics, Inc. Common Stock (ACRV) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.49 (in line with the analyst consensus of $-0.49). ACRV has beaten EPS estimates for 6 consecutive quarters. The next ACRV earnings date is expected around September 1, 2026.
Each quarter, investors track ACRV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACRV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACRV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACRV earnings · 4 questionsAcrivon Therapeutics, Inc. Common Stock's next earnings report is expected around September 1, 2026. ACRV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACRV historically reports after market close (AMC).
ACRV earnings datewhen is ACRV earningsACRV next earnings datewhen does ACRV report earningsACRV earnings calendar
▸ Source: FMP · Acrivon Therapeutics, Inc. Common Stock SEC filings · US GAAP · Acrivon Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026